This webinar highlights strategies for identifying patients who may benefit from the latest advances in age-related macular degeneration therapies and the potential advantages that longer duration therapies may offer. Drs. Dunbar, Goldberg, and Steen will also discuss potential strategies to overcome barriers to adherence.
This activity is supported by an unrestricted educational grant from Genentech, a member of the Roche Group.
Upon completion of this activity, the participant should be able to:
Evolve Medical Education, LLC is a COPE-accredited administrator.
Sponsored by
This activity, COPE Activity Number 126394, is accredited by COPE for continuing education for optometrists. This course is approved for 1 hour of CE.
Course #: 85354-TD
Activity #: 126394
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.
Roger A. Goldberg, MD, MBA
Vitreoretinal Specialist
Bay Area Retina Associates
Volunteer Faculty
California Pacific Medical Center
Walnut Creek, CA
Mark T. Dunbar, OD, FAAO
Director of Optometry
Bascom Palmer Eye Institute
University of Miami Health System
Miami, FL
Jessica Steen, OD, FAAO
Associate Professor
Nova Southeastern University
College of Optometry
Fort Lauderdale, FL
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Roger A. Goldberg, MD, MBA, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Annexon Biosciences, Apellis Pharmaceuticals, Boehringer Ingelheim, Carl Zeiss Meditec, Coherus Biosciences, EyePoint Pharmaceuticals, Genentech/Roche, Outlook, and Regeneron. Grant/Research Support: Affamed, Annexon Biosciences, Apellis Pharmaceuticals, Boehringer Ingelheim, Carl Zeiss Meditec, EyePoint Pharmaceuticals, Genentech/Roche, Janssen, Neurotech, and Novo Nordisk. Speaker's Bureau: Apellis Pharmaceuticals, Biogen, and Genentech/Roche.
Mark T. Dunbar, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Advisory Board: Allergan, Carl Zeiss Meditec, Genentech, Reed Exhibitions, Regeneron, and Tarsus Pharmaceuticals. Consultant: Allergan, Avellino, Carl Zeiss Meditec, Genentech, Iveric Bio, Orasis Pharmaceuticals, Regeneron, and Visus. Speaker's Bureau: Allergan, Carl Zeiss Meditec, and Regeneron.
Jessica Steen, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Bausch + Lomb, Ocuphire Pharma, OcuTerra, Peripherex, Santen, and Théa Pharma. Shareholder: Clearside Biomedical. Speaker's Bureau: Bausch + Lomb, Carl Zeiss Meditec, Oyster Point Pharma, and Théa Pharma.
The Evolve staff, planners, and peer reviewer have no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Genentech, a member of the Roche Group.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Release Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
